Skip to main content
NewsPublications

Scientific articles in 2018

By 31 December 2018January 26th, 2022No Comments

Scientific articles in 2018

ADx NeuroSciences is an R&D company and its people are involved in many R&D studies and publications. Find an overview of the 2018 articles with ADx involvement below.

1. C-Reactive Protein, Plasma Amyloid-β Levels, and Their Interaction With Magnetic Resonance Imaging Markers.

Hilal S, Ikram MA, Verbeek MM, Franco OH, Stoops E, Vanderstichele H, Niessen WJ, Vernooij MW.
Stroke. 2018 Nov;49(11):2692-2698. doi: 10.1161/STROKEAHA.118.022317.

2. Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy.

Schmitz M, Villar-Piqué A, Llorens F, Gmitterová K, Hermann P, Varges D, Zafar S, Lingor P, Vanderstichele H, Demeyer L, Stoops E, Trojanowski JQ, Lee VM, Zerr I.
Mol Neurobiol. 2018 Aug 22. doi: 10.1007/s12035-018-1313-4. [Epub ahead of print].

3. Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid – method comparison and round robin study.

Mollenhauer B, DuBois BF, Drake D, Duong J, Blennow K, El-Agnaf O, Shaw LM, Masucci J, Taylor P, Umek RM, Dunty IM, Smith CL, Stoops E, Vanderstichele H, Schmid AW, Moniatte M, Zhang J, Kruse N, Lashuel HA, Teunissen C, Schubert T, Dave KD, Hutten SJ, Zetterberg H.
J Neurochem. 2018 Aug 20. doi: 10.1111/jnc.14569. [Epub ahead of print].

4. Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study.

Hilal S, Wolters FJ, Verbeek MM, Vanderstichele H, Ikram MK, Stoops E, Ikram MA, Vernooij MW.
Alzheimers Res Ther. 2018 Jun 30;10(1):63. doi: 10.1186/s13195-018-0395-6

5. Commutability of the certified reference materials for the standardization of β-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β-amyloid 1-40 measurements.

Andreasson U, Kuhlmann J, Pannee J, Umek RM, Stoops E, Vanderstichele H, Matzen A, Vandijck M, Dauwe M, Leinenbach A, Rutz S, Portelius E, Zegers I, Zetterberg H, Blennow K.
Clin Chem Lab Med. 2018 Nov 27;56(12):2058-2066. doi: 10.1515/cclm-2018-0147.

6. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer’s disease diagnosis: A review.

Hansson O, Mikulskis A, Fagan AM, Teunissen C, Zetterberg H, Vanderstichele H, Molinuevo JL, Shaw LM, Vandijck M, Verbeek MM, Savage M, Mattsson N, Lewczuk P, Batrla R, Rutz S, Dean RA, Blennow K.
Alzheimers Dement. 2018 Oct;14(10):1313-1333. doi: 10.1016/j.jalz.2018.05.008. Epub 2018 Jun 23. Review.

7. Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR.

Lehmann S, Delaby C, Boursier G, Catteau C, Ginestet N, Tiers L, Maceski A, Navucet S, Paquet C, Dumurgier J, Vanmechelen E, Vanderstichele H, Gabelle A.
Front Aging Neurosci. 2018 May 28;10:138. doi: 10.3389/fnagi.2018.00138. eCollection 2018.

8. Plasma Aβ (Amyloid-β) Levels and Severity and Progression of Small Vessel Disease.

van Leijsen EMC, Kuiperij HB, Kersten I, Bergkamp MI, van Uden IWM, Vanderstichele H, Stoops E, Claassen JAHR, van Dijk EJ, de Leeuw FE, Verbeek MM.
Stroke. 2018 Apr;49(4):884-890. doi: 10.1161/STROKEAHA.117.019810. Epub 2018 Mar 14.

9. Automation on an Open-Access Platform of Alzheimer’s Disease Biomarker Immunoassays.

Gille B, Dedeene L, Stoops E, Demeyer L, Francois C, Lefever S, De Schaepdryver M, Brix B, Vandenberghe R, Tournoy J, Vanderstichele H, Poesen K.
SLAS Technol. 2018 Apr;23(2):188-197. doi: 10.1177/2472630317750378. Epub 2018 Jan 18.

10. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer’s Disease Pathology Between Three Independent Assay Platforms.

Doecke JD, Rembach A, Villemagne VL, Varghese S, Rainey-Smith S, Sarros S, Evered LA, Fowler CJ, Pertile KK, Rumble RL, Trounson B, Taddei K, Laws SM, Macaulay SL, Bush AI, Ellis KA, Martins R, Ames D, Silbert B, Vanderstichele H, Masters CL, Darby DG, Li QX, Collins S; AIBL Research Group.
J Alzheimers Dis. 2018;61(1):169-183. doi: 10.3233/JAD-170128.

11. Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimer’s Disease: A Pilot Study.

Schipke CG, De Vos A, Fuentes M, Jacobs D, Vanmechelen E, Peters O.
Dement Geriatr Cogn Dis Extra. 2018 Aug 6;8(2):277-289. doi: 10.1159/000489847. eCollection 2018 May-Aug.

12. Digital ELISA for the quantification of attomolar concentrations of Alzheimer’s disease biomarker protein Tau in biological samples.

Pérez-Ruiz E, Decrop D, Ven K, Tripodi L, Leirs K, Rosseels J, van de Wouwer M, Geukens N, De Vos A, Vanmechelen E, Winderickx J, Lammertyn J, Spasic D.
Anal Chim Acta. 2018 Jul 26;1015:74-81. doi: 10.1016/j.aca.2018.02.011. Epub 2018 Feb 17.

13. Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study.

Willemse EAJ, De Vos A, Herries EM, Andreasson U, Engelborghs S, van der Flier WM, Scheltens P, Crimmins D, Ladenson JH, Vanmechelen E, Zetterberg H, Fagan AM, Blennow K, Bjerke M, Teunissen CE.
Clin Chem. 2018 Jun;64(6):927-937. doi: 10.1373/clinchem.2017.283028. Epub 2018 Mar 9.

14. Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer’s disease.

Kirsebom BE, Nordengen K, Selnes P, Waterloo K, Torsetnes SB, Gísladóttir B, Brix B, Vanmechelen E, Bråthen G, Hessen E, Aarsland D, Fladby T.
Alzheimers Dement (N Y). 2018 Nov 10;4:617-627. doi: 10.1016/j.trci.2018.10.003. eCollection 2018.